NewcelX rises after raising funds at premium to boost diabetes program

NewcelX AG

01/04/2026 12:36

** Shares of biotech firm NewcelX NCEL.O rise 13.7% to $2.41 premarket

** Co says it raised funds via a private share placement priced 30% above its last close

** NewcelX is developing stem cell treatments for Type 1 diabetes, a condition where the body cannot make insulin to control blood sugar - NCEL

** Co says it sold ~491,000 shares and warrants for ~687,000 more shares, with existing shareholders participating

** Proceeds, along with a previously announced $25 million equity line, will fund its lead diabetes program NCEL-101 and other pipeline work - NCEL

** Co says deal expected to close around April 15, subject to standard conditions

** As of last close, stock up ~12% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))